Skip to content

Comparison of Meperidine and Fentanyl on Pain Scale and QOL in Brachytherapy

Comparison of Meperidine and Fentanyl on Pain Scale and Quality of Life in Cervical Cancer Patients Receiving Brachytherapy: A Double-blind, Randomized Controlled Trial

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02684942
Enrollment
40
Registered
2016-02-18
Start date
2012-10-31
Completion date
2014-03-31
Last updated
2017-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pain, Quality of Life

Keywords

Meperidine, Fentanyl, Pain management, brachytherapy

Brief summary

Purpose: To compare the pain level and quality of life of the two sedation regimens consisting of diazepam in combination with meperidine or fentanyl. Materials and methods: A total of 40 patients (160 sessions of brachytherapy), unselected brachytherapy out patients at Chulabhorn Hospital, Thailand were enrolled with informed consent and randomized to receive meperidine or fentanyl. Data of perceived pain (according to standard 10-cm visual analog scales \[VAS\]), and perceived Quality of life (EQ-5D) were collected. Patients and all brachytherapy staffs directly involved with the procedure were blinded about the drug used.

Detailed description

Methods Patients Unselected, forty female adults, aged 20 years old or older, diagnosed with cervical cancer and treated with brachytherapy as outpatients at Chulabhorn Hospital, Thailand between June 2011 and September 2012 were enrolled in the study with their informed consents. The study was approved by The Chulabhorn Research Institutional Review Board and Chulabhorn Ethics committee. All the patients were treated with four sessions of ICRT(Intracavitary Radiation Therapy). Inclusion criteria were: Age 20 - 80 years, can understand and provide information, no trouble hearing and good conscious, agree to participated and had performance levels at ECOG 0-2. The patients were randomized to receive either meperidine (1 mg/kg) or fentanyl (1 ug/kg) with diazepam 10 mg both. Nursing staffs who prepared the drugs picked the drugs from lotteries organized into 6 lots on it. Procedures Perceived pain score according to standard 10-cm visual analog scales (VAS) was assessed prior to treatment and every 15 minutes from the start to the end of the ICRT procedure. Perceived Quality of life (EQ-5D) was assessed before the treatment and immediately after the completion of each brachytherapy treatment session. Information regarding which drug was used was concealed to all the patients and brachytherapy staffs directly involved with the procedures. The procedures involved a radiation oncologist, two nurses, a practical nurse, a radiotherapist, and a medical physicist. Firstly, before the procedure the patients must NPO(Nothing per oral) for 6 hours and was inserted with intravenous catheter for IV sedation drug depending on the randomized drug that they received. Secondly, the patients laid down on brachytherapy stretcher and were treated according to the standard ICRT protocol. Each randomized patient had 4 fractions of ICRT, so a single patient will receive Fentanyl and Diazepam 2 fractions and Meperidine and Diazepam 2 fractions. The drugs used were diluted with normal saline to 10 ml. and labeled as Protocol drug. The actual content within the syringes was known only to a nurse that did not directly involve in the study. Syringes prepared for the meperidine group contained 50 mg of meperidine, while syringes prepared for the fentanyl group contained 100 mg of fentanyl. Both drugs were drawn into 10-cc syringes and appeared colorless.

Interventions

DRUGMeperidine

Injection meperidine 1 mg/kg with diazepam 0.1 mg/kg.to intravenous 5 minutes before inserting the applicator and then when the patients had pain score greater or equal to 4. All patients received supplement oxygen cannula 3 LPM continuously monitored for saturation, pulse and monitored every 5 minutes for blood pressure.

DRUGFentanyl

Injection meperidine 1 mg/kg to intravenous 5 minute before insertion the applicator and then when the patients had pain score greater than or equal to 4. All patients received supplement oxygen cannula 3 LPM continuously monitored for saturation, pulse and monitored every 5 minutes for blood pressure.

Sponsors

Chulabhorn Cancer Center
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Outcomes Assessor)

Eligibility

Sex/Gender
FEMALE
Age
20 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* Aged 20 years old or older, * Diagnosed with cervical cancer * On course of external Radiation therapy * Treated with brachytherapy 4 times.

Exclusion criteria

* Pregnant * Previously underwent intracavitary brachytherapy * Illiterate

Design outcomes

Primary

MeasureTime frameDescription
Pain ScoreFrom date of the first fraction until date of the last fraction of brachytherapy, once a week for four weeksPerceived pain score according to standard 10-cm visual analog scales (VAS) was assessed before injection of medicine for every 15 minutes up to 120 minutes.The minimum and maximum scores were 0, 10. Score 0 means no pain, 1-3 mild pain, 4-6 moderate pain, 7-9 severe pain and 10 worst pain.

Secondary

MeasureTime frameDescription
Quality of LifeFrom date of the first fraction of brachytherapy until date of the last fraction of brachytherapy,once a week for 4 weeksPerceived Quality of life (EQ-5D) was assessed before the first brachytherpy and immediately after completion of each of the 4 brachytherapy fractions. The EQ-5D have 5 dimensions: mobility, self-care, usual activities, topics each content 3 responses: no problems, some problems, extreme problems.

Other

MeasureTime frameDescription
Ovoids Sizeafter complete applicator insertion.Size of ovoids that a pair part of brachytherapy applicator insert in vagina trough cervix.
Tumor SizeBefore insert applicator in each fraction of brachytherapy.Size of tumor at cervix measured by the doctor before insert applicator.
Meperidine Doseafter complete treatment.Sum of meperidine dose when finish each fraction of brachytherapy
Fentanyl Doseafter complete treatment.Sum of fentanyl dose when finish each fraction of brachytherapy

Participant flow

Recruitment details

The study design is cross-over in female outpatients with cervical cancer (age, 20-80 years) stage IB-IVB treated with four fractions of brachytherapy from June 2013 to September 2014 were enrolled in the study.

Pre-assignment details

Forty patients with cervical cancer were enrolled in the study. The exclusion criteria were prior pelvic brachytherapy and a history of allergy to meperidine, fentanyl, or benzodiazepine and none were subsequently excluded.

Participants by arm

ArmCount
All Participants
All participants who enrolled to this study.
40
Total40

Baseline characteristics

CharacteristicAll Participants
Age, Continuous56.7 years
STANDARD_DEVIATION 12.9
FIGO stage
IB
5 participants
FIGO stage
IIA1
2 participants
FIGO stage
IIA2
1 participants
FIGO stage
IIB
16 participants
FIGO stage
IIIB
15 participants
FIGO stage
IVB
1 participants
Radiation modality
2D, two-dimensional
30 participants
Radiation modality
3D conformal
10 participants
Sex: Female, Male
Female
40 Participants
Sex: Female, Male
Male
0 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
0 / 400 / 40
other
Total, other adverse events
0 / 400 / 40
serious
Total, serious adverse events
0 / 400 / 40

Outcome results

Primary

Pain Score

Perceived pain score according to standard 10-cm visual analog scales (VAS) was assessed before injection of medicine for every 15 minutes up to 120 minutes.The minimum and maximum scores were 0, 10. Score 0 means no pain, 1-3 mild pain, 4-6 moderate pain, 7-9 severe pain and 10 worst pain.

Time frame: From date of the first fraction until date of the last fraction of brachytherapy, once a week for four weeks

ArmMeasureGroupValue (MEAN)Dispersion
MeperidinePain Score15 minute0.59 units on a scaleStandard Deviation 1.38
MeperidinePain Score60 minute0.61 units on a scaleStandard Deviation 1.48
MeperidinePain Score0 minute0.49 units on a scaleStandard Deviation 1.18
MeperidinePain Score75 minute0.49 units on a scaleStandard Deviation 0.99
MeperidinePain Score30 minute1.05 units on a scaleStandard Deviation 1.76
MeperidinePain Score90 minute0.24 units on a scaleStandard Deviation 0.8
MeperidinePain Score105 minute0.24 units on a scaleStandard Deviation 0.8
MeperidinePain Scorebaseline0.04 units on a scaleStandard Deviation 0.25
MeperidinePain Score120 minute0.24 units on a scaleStandard Deviation 0.8
MeperidinePain Score45 minute1.33 units on a scaleStandard Deviation 2.09
FentanylPain Score120 minute0.13 units on a scaleStandard Deviation 0.58
FentanylPain Scorebaseline0.14 units on a scaleStandard Deviation 0.55
FentanylPain Score0 minute0.40 units on a scaleStandard Deviation 1.16
FentanylPain Score15 minute0.65 units on a scaleStandard Deviation 1.21
FentanylPain Score30 minute1.24 units on a scaleStandard Deviation 2.21
FentanylPain Score45 minute1.70 units on a scaleStandard Deviation 2.48
FentanylPain Score60 minute0.81 units on a scaleStandard Deviation 1.83
FentanylPain Score75 minute0.53 units on a scaleStandard Deviation 1.12
FentanylPain Score105 minute0.13 units on a scaleStandard Deviation 0.58
FentanylPain Score90 minute0.13 units on a scaleStandard Deviation 0.58
Secondary

Quality of Life

Perceived Quality of life (EQ-5D) was assessed before the first brachytherpy and immediately after completion of each of the 4 brachytherapy fractions. The EQ-5D have 5 dimensions: mobility, self-care, usual activities, topics each content 3 responses: no problems, some problems, extreme problems.

Time frame: From date of the first fraction of brachytherapy until date of the last fraction of brachytherapy,once a week for 4 weeks

Population: Pain score in each fraction.

ArmMeasureGroupValue (NUMBER)
MeperidineQuality of LifeSome problem in self-care11 participants
MeperidineQuality of LifeSevere problem in usual activities2 participants
MeperidineQuality of LifeSome problems in mobility16 participants
MeperidineQuality of LifeNo problem in pain/discomfort27 participants
MeperidineQuality of LifeSevere problem in self-care0 participants
MeperidineQuality of LifeSome problem in pain/discomfort49 participants
MeperidineQuality of LifeNo problem in self-care68 participants
MeperidineQuality of LifeSevere problem in pain/discomfort3 participants
MeperidineQuality of LifeNo problem in usual activities55 participants
MeperidineQuality of LifeNo problem in anxiety/depression46 participants
MeperidineQuality of LifeSevere problems in mobility1 participants
MeperidineQuality of LifeSome problem in anxiety/depression32 participants
MeperidineQuality of LifeSome problem in usual activities22 participants
MeperidineQuality of LifeSevere problem in anxiety/depression1 participants
MeperidineQuality of LifeNo problems in mobility62 participants
FentanylQuality of LifeSevere problem in anxiety/depression2 participants
FentanylQuality of LifeNo problems in mobility58 participants
FentanylQuality of LifeSome problems in mobility18 participants
FentanylQuality of LifeSevere problems in mobility1 participants
FentanylQuality of LifeNo problem in self-care69 participants
FentanylQuality of LifeSome problem in self-care6 participants
FentanylQuality of LifeSevere problem in self-care2 participants
FentanylQuality of LifeNo problem in usual activities53 participants
FentanylQuality of LifeSome problem in usual activities21 participants
FentanylQuality of LifeSevere problem in usual activities3 participants
FentanylQuality of LifeNo problem in pain/discomfort23 participants
FentanylQuality of LifeSome problem in pain/discomfort53 participants
FentanylQuality of LifeSevere problem in pain/discomfort1 participants
FentanylQuality of LifeNo problem in anxiety/depression42 participants
FentanylQuality of LifeSome problem in anxiety/depression33 participants
Other Pre-specified

Fentanyl Dose

Sum of fentanyl dose when finish each fraction of brachytherapy

Time frame: after complete treatment.

Population: Participants received 4 fraction of brachytherapy. Thus all 160 fractions separated to two group of drug and analysis data in each group.

ArmMeasureValue (MEAN)Dispersion
MeperidineFentanyl Dose100.18 ug.Standard Deviation 0.32
Other Pre-specified

Meperidine Dose

Sum of meperidine dose when finish each fraction of brachytherapy

Time frame: after complete treatment.

Population: Participants received 4 fraction of brachytherapy. Thus all 160 fractions separated to two group of drug and analysis data in each group.

ArmMeasureValue (MEAN)Dispersion
MeperidineMeperidine Dose50.13 mg.Standard Deviation 0.26
Other Pre-specified

Ovoids Size

Size of ovoids that a pair part of brachytherapy applicator insert in vagina trough cervix.

Time frame: after complete applicator insertion.

Population: Each patient was treated with 4 fractions of brachytherapy.

ArmMeasureValue (MEDIAN)
MeperidineOvoids Size2 Centimeter
FentanylOvoids Size2 Centimeter
Other Pre-specified

Tumor Size

Size of tumor at cervix measured by the doctor before insert applicator.

Time frame: Before insert applicator in each fraction of brachytherapy.

Population: Participants received 4 fraction of brachytherapy. Thus all 160 fractions separated to two group of drug and analysis data in each group.

ArmMeasureValue (MEAN)Dispersion
MeperidineTumor Size2.23 CM.Standard Deviation 1.29
FentanylTumor Size2.21 CM.Standard Deviation 1.25

Source: ClinicalTrials.gov · Data processed: Mar 10, 2026